Significant median OS demonstrated in the VISION trial: 15.3 months with PLUVICTO + BSOC vs 11.3 months with BSOC alone (HR=0.62; 95% CI, 0.52-0.74; P<0.001)1,2
BSOC, best standard of care; HR, hazard ratio; mCRPC, metastatic castration-resistant prostate cancer; OS, overall survival; PSMA+, prostate-specific membrane antigen positive.